Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients.
Publication/Presentation Date
10-1-2024
Abstract
INTRODUCTION: Intravenous vitamin C was administered following hematopoietic stem cell transplant to mitigate nonrelapse mortality (NRM) in a Phase II clinical trial.
METHODS: Patients with advanced hematologic malignancies received IV vitamin C, 50 mg/kg/day, in three divided doses on days 1-14 after HSCT, followed by 500 mg bid oral until 6 months.
RESULTS: All patients enrolled (55) were deficient in vitamin C at day 0 and had restoration to normal levels. Vitamin C recipients had a trend for lower nonrelapse mortality (NRM, 11% vs. 25%,
CONCLUSION: In patients undergoing allogeneic HSCT, repletion of vitamin C is feasible and may reduce NRM and improve overall survival. Randomized trials in large uniform cohorts of patients are needed to confirm the utility of this easily available and inexpensive therapy.
Volume
5
Issue
5
First Page
1043
Last Page
1047
ISSN
2688-6146
Published In/Presented At
Simmons, G. L., Sabo, R., Qayyum, R., Aziz, M., Martin, E., Bernard, R. J., Sriparna, M., McIntire, C., Krieger, E., Brophy, D. F., Natarajan, R., Iii, A. F., Roberts, C. H., & Toor, A. (2024). Feasibility of intravenous vitamin C supplementation in allogeneic hematopoietic cell transplant recipients. EJHaem, 5(5), 1043–1047. https://doi.org/10.1002/jha2.995
Disciplines
Medicine and Health Sciences
PubMedID
39415933
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article